The startup will be headed by CEO Ron Renaud, who previously led Cerevel Therapeutics — a developer of drugs for neurological conditions — and oversaw its acquisition by AbbVie in an $8.7 billion deal ...

Ozempic-curious people are taking a novel approach to using the blockbuster weight loss drug — and some doctors are even ...

Market: Industry Trends and Global Forecasts to 2035: Distribution by Type of Molecule, Active Compound Used, Type of GLP-1 ...

In a groundbreaking move, Eli Lilly LLY is set to test its weight-loss medications on individuals who are not overweight but are at risk of gaining weight.

Demand forweight-loss drugs has grown at an astonishing rate in recent years, driving share prices of healthcare giants such ...

Eli Lilly is considering testing its blockbuster weight-loss drugs in people who are not overweight but are at risk of weight ...

With early phase 1 data now out in the wild, metabolic disease outfit Metsera is wasting no time locking down supplies of its ...

Kailera Therapeutics has launched into the increasingly crowded obesity space with a portfolio of assets acquired from China ...

Although Viking Therapeutics (NASDAQ: VKTX) is a busy company, on Monday its stock moved because of external news. A pundit ...

Alzheimer's disease (AD) has become a focal point in the pharmaceutical industry as recent drugs such as Leqembi and Kisunla have received ...

"Pharmacy middlemen" are to blame for the high cost of drugs like Wegovy and Ozempic, according to Novo Nordisk's CEO. Is ...

If you’ve been trying to reach a healthier weight, you may be considering semaglutide medications like Ozempic and Wegovy.